← ANALYST RATINGS · TIPRANKS
ACADIA Pharmaceuticals (ACAD): analyst forecast and price target
Analyst consensus
Moderate Buy8 Buy3 Hold0 Sell
Ratings of 11 analysts in the last 3 months · top analysts only12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $31.82, the highest $37.00, the lowest $23.00. The average is +66.4% from the last price of $19.12.
Analyst ratings 17
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $49.00 → $23.00−53.1% | Hold | +20.3% | Downgrade | 13.10.26on TipRanks 07:25 | −4.1%next day +4.5% | ↗ |
| Malcolm Hoffman★★★★★★★★★★#7666 · hits 100% · avg +34.9% | BMO Capital | $34.00 | Buy | +77.8% | Reiterated | 12.10.26on TipRanks 13:10 | −1.8%next day −4.1% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $31.00 | Buy | +62.1% | Reiterated | 09.10.26on TipRanks 06:11 | +0.4%next day −1.8% · 5 days −1.4% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $37.00 → $36.00−2.7% | Buy | +88.3% | Reiterated | 08.10.26on TipRanks 08:50 | +0.1%next day +0.4% · 5 days +0.9% | ↗ |
| Ananda Ghosh★★★★★★★★★★#1171 · hits 53% · avg +20.8% | H.C. Wainwright | $37.00 → $33.00−10.8% | Buy | +72.6% | Reiterated | 25.09.26on TipRanks 10:50 | −7.3%next day 0.0% · 5 days −3.3% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $38.00 → $31.00−18.4% | Buy | +62.1% | Reiterated | 25.09.26on TipRanks 08:35 | −7.3%next day 0.0% · 5 days −3.3% | ↗ |
| Sumant Kulkarni★★★★★★★★★★#670 · hits 50% · avg +14.2% | Canaccord Genuity | $36.00 | Buy | +88.3% | Reiterated | 25.09.26on TipRanks 07:10 | −7.3%next day 0.0% · 5 days −3.3% | ↗ |
| Jason Butler★★★★★★★★★★#412 · hits 51% · avg +18.3% | Citizens JMP | $36.00 → $33.00−8.3% | Buy | +72.6% | Reiterated | 25.09.26on TipRanks 05:50 | −7.3%next day 0.0% · 5 days −3.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $32.00 → $28.00−12.5% | Buy | +46.4% | Reiterated | 25.09.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $31.00 → $27.00−12.9% | Hold | +41.2% | Downgrade | 25.09.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $31.00 → $28.00−9.7% | Buy | +46.4% | Reiterated | 25.09.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $31.00 → $28.00−9.7% | Hold | +46.4% | Downgrade | 25.09.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $32.00 → $29.00−9.4% | Buy | +51.7% | Reiterated | 25.09.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $32.00 → $29.00−9.4% | Buy | +51.7% | Reiterated | 25.09.26on TipRanks 00:05 | — | |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $40.00 → $33.00−17.5% | Buy | +72.6% | Reiterated | 25.09.26on TipRanks Sep 24 13:05 | −12.7%next day −7.3% · 5 days −9.9% | ↗ |
| Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% | Needham | $41.00 → $35.00−14.6% | Buy | +83.1% | Reiterated | 25.09.26on TipRanks Sep 24 09:45 | −12.7%next day −7.3% · 5 days −9.9% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $27.00 → $28.00+3.7% | Hold | +46.4% | Assigned | 25.08.26on TipRanks 07:11 | +2.8%next day −3.3% · 5 days −5.0% | ↗ |
| Matthew Hershenhorn★★★★★★★★★★#4544 · hits 100% · avg +85.8% | Oppenheimer | $23.00 → $25.00+8.7% | Hold | +30.8% | Reiterated | 05.08.26on TipRanks 07:55 | +6.3%next day −1.1% · 5 days +1.9% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $25.00 | Hold | +30.8% | Reiterated | 05.08.26on TipRanks 07:36 | +6.3%next day −1.1% · 5 days +1.9% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $37.00 | Buy | +93.5% | Assigned | 05.08.26on TipRanks 02:55 | +6.3%next day −1.1% · 5 days +1.9% | ↗ |
| Unknown Analyst | Guggenheim | — | Hold | — | Reiterated | 04.08.26on TipRanks Aug 5 08:01 | +4.2%next day +6.3% · 5 days +8.4% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $33.00 | Buy | +72.6% | Reiterated | 06.05.26on TipRanks May 7 07:20 | −5.3%next day +5.3% · 5 days +2.1% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $34.00 | Buy | +77.8% | Assigned | 04.03.26on TipRanks 07:00 | +3.3%next day −3.7% · 5 days −4.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering ACADIA Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $33.36 at a price of $20.15 (+65.5%); now: $31.43 at $19.12 (+64.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 1 | 5 | 7 |
| Buy | 7 | 9 | 9 | 17 | 15 | 13 |
| Hold | 1 | 2 | 4 | 7 | 7 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.20 (from $0.11 to $0.29). Last quarter: $0.18.
Sales
Next quarter’s sales estimate — $332M (from $325M to $339M). Last quarter: $308M.
Best top-analyst consensus in the sector · Healthcare
About ACADIA Pharmaceuticals
- CEO: Catherine E. Owen Adams
- Employees: 797
- 12830 El Camino Real, San Diego, CA, 92130, US
- www.acadia.com
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Data from the stock’s TipRanks forecast page, read 12 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗